Chikungunya Vaccine in Valneva Positive Preliminary Results | world and science

Chikungunya Vaccine in Valneva Positive Preliminary Results |  world and science

Candidate vaccine ‘also shown to be highly immunogenic, even in elderly participants’France Press agency

Posted on 05/08/2021 8:51 AM

Paris – The French-Austrian laboratory Valneva announced Thursday 5 “positive preliminary results” for the vaccine against chikungunya, which is currently undergoing phase three testing.

Valneva said in a statement that the vaccine tested on 4,115 adults in the United States produced “neutralizing antibodies in 98.5% of participants 28 days after a single injection.”

This number is well above the 70% limit for this immunization, agreed with the US regulatory body, the Food and Drug Administration, “for use in a marketing authorization application.”

The company said the candidate vaccine “also demonstrated to be highly immunogenic, even in older participants” and was “generally well tolerated”.

“These first results from a phase 3 (last before commercialization) trial of a chikungunya vaccine mean we are one step closer to addressing this important and growing unmet public health threat,” said Juan Carlos Jaramillo, medical director for the City of Valneva. , Quoted in the press release.

Final results are expected over the next six months, with the goal of bringing the product to market “as soon as possible”.

In addition to a vaccine against chikungunya, a virus transmitted by mosquitoes, Valneva is also developing an immune system against covid-19, which is currently in phase 3 clinical trials.

In addition, the Lyme disease serum is in phase II clinical trials in humans, which is the intermediate step to ensuring its efficacy.

See also  Israel and Switzerland report first cases of monkeypox as Spain buys vaccines

By Andrea Hargraves

"Wannabe internet buff. Future teen idol. Hardcore zombie guru. Gamer. Avid creator. Entrepreneur. Bacon ninja."